Diffuse large B-cell lymphoma (DLBCL) Clinical Trials
Recruiting diffuse large b-cell lymphoma (dlbcl) studies with sites across the US, sourced from ClinicalTrials.gov and refreshed daily. Free to join — find one near you below.
Clinical trials study new ways to prevent, detect, or treat diffuse large b-cell lymphoma (dlbcl). Joining one can give you access to investigational treatments and close monitoring by a specialist research team — at no cost — while helping advance care for others. Below are recruiting diffuse large b-cell lymphoma (dlbcl) studies with sites across the US; use the location tools to find ones near you.
What to expect
- Screening first. The study team reviews your eligibility before anything else — there's no obligation to continue.
- Informed consent. You'll get a full explanation of the study, its potential risks and benefits, and can withdraw at any time.
- No cost to you. Study visits, tests, and the investigational treatment are covered; many studies reimburse travel.
Recruiting diffuse large b-cell lymphoma (dlbcl) trials
Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients
GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma
A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL
MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma
External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment
LME-Guided Precision Combination Therapy in B-cell Lymphoma Patients After CD19 CAR-T Failure
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma
Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma
NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
Glofitamab in Real Life
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL
UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
CHiR Therapy for Elderly DLBCL Intolerant to Chemo
Diffuse large B-cell lymphoma (DLBCL) clinical trials — common questions
Are diffuse large b-cell lymphoma (dlbcl) clinical trials free to join?
Yes. Participating in a diffuse large b-cell lymphoma (dlbcl) clinical trial is free — study-related visits, tests, and the investigational treatment are provided at no cost to you. Many studies also reimburse travel and time. You never pay to take part.
Who can join a diffuse large b-cell lymphoma (dlbcl) clinical trial?
Each diffuse large b-cell lymphoma (dlbcl) study sets its own eligibility criteria — typically based on age, medical history, current treatments, and overall health. Every trial listed here shows its criteria, and the study team confirms your eligibility before enrollment. You can review and apply to any that look like a fit.
How do I find a diffuse large b-cell lymphoma (dlbcl) trial near me?
Use the location controls above. We'll show recruiting diffuse large b-cell lymphoma (dlbcl) trials with sites near you, sorted by distance. You can widen the radius or share your exact location for the closest matches.
How many diffuse large b-cell lymphoma (dlbcl) trials are recruiting right now?
We're currently tracking roughly 99 recruiting diffuse large b-cell lymphoma (dlbcl) trials with US sites, sourced from ClinicalTrials.gov and refreshed daily.
Looking for a specific location? Browse trials by city and state.